John Seymour, MD, discusses the development and clinical application of BCL-2 inhibitors for the treatment of CLL.

APG-2575（Lisaftoclax）是亚盛医药自主研发的、具全球best-in-class潜力的新型口服Bcl-2选择性抑制剂，在多种血液肿瘤和实体瘤治疗领域具备广阔的治疗潜力。亚盛医药将在此次ASH年会上，口头报告该品种治疗复发/难治（R/R）多发性骨髓瘤 ...

Ascentage Pharma, a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies.

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...

Members of the Bcl-2 family are critical regulators of apoptosis and have become attractive targets for the development of anti-cancer drugs. The latest discovery of small-molecule inhibitors of ...

Scientists from Duke-NUS Medical School and their collaborators have identified an inherited genetic variation prevalent ...

Aumolertinib showed improved PFS in NSCLC and ivonescimab outperforms pembrolizumab in advanced cases. Plus, insights into CAR T-cell therapy and its associated AEs are discussed in relapsed multiple ...

Ascentage Pharma Group International (HK:6855) has released an update. Ascentage Pharma Group International is showcasing promising results ...

Lomond Therapeutics, Inc., a clinical-stage biotechnology company dedicated to discovering and developing potentially best-in-class and first-in-class medicines for the treatment of hematological ...

ABT199/venetoclax, an inhibitor of the pro-survival BCL-2 protein, has improved AML treatment. However, its efficacy in hematopoietic stem cell transplantation (HSCT) when combined with other ...

Developed by Ascentage Pharma, olverembatinib is the first China -approved third-generation BCR:ABL1 inhibitor, currently being jointly commercialized in China by Ascentage Pharma and Innovent ...